Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2019  |  Volume : 32  |  Issue : 4  |  Page : 1506-1511

Soluble suppression of tumorigenisity 2 as an indicator of severity of heart failure in children with congenital acyanotic heart diseases


1 Department of Pediatrics, Faculty of Medicine, Menoufia University, Shebin El Kom, Egypt
2 Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Menoufia University, Shebin El Kom, Egypt
3 Department of Pediatric, Pediatrics at Ministry of Health, Shebin El Kom, Egypt

Correspondence Address:
Rabab M Shaban
Tala, Menoufia
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mmj.mmj_154_19

Rights and Permissions

Objective We aimed to evaluate the role of soluble suppression of tumorigenisity 2 (sST2) as an indicator of severity of heart failure (HF) in children with congenital acyanotic heart diseases. Background HF in congenital heart diseases (CHD) is a serious problem encountered in early infancy or later. It is a significant cause of morbidity and mortality in children with CHD. SST2 is currently gaining interest as a biomarker in cardiac disease. Patients and methods A prospective comparative study was conducted on 60 children having CHD with left-to-right shunt from the Pediatric Department of Menoufia University Hospitals between August 2017 and August 2018 and were divided into two groups: group 1: 30 children with manifestation of HF. Group 2: 30 children without manifestation of HF. In addition, 25 age-matched and sex-matched healthy children were set as a control group. All children were subjected to a full clinical history and examination. Serum level of sST2 were determined. Results Level of sST2 was 82.2 ± 22.3 and 25.63 ± 19.33 ng/ml in patients with and without HF, respectively. SST2 was significantly higher in patients who developed HF than in those without HF (P < 0.001). SST2 was significantly elevated with increased severity of HF (P < 0.001), wherein it was 25.63 ± 19.3, 55.5 ± 2.6, 86.1 ± 7.7, and 109.9 ± 6.4 ng/ml in patients with ROSS class I, II, III, and IV, respectively. Conclusion SST2 is a promising novel cardiac biomarker that could reflect the severity of HF.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1361    
    Printed42    
    Emailed0    
    PDF Downloaded147    
    Comments [Add]    

Recommend this journal